Ascendis Pharma A/S (ASND)
| Market Cap | 16.24B |
| Revenue (ttm) | 1.20B +113.4% |
| Net Income | 847.43M |
| EPS | 13.38 |
| Shares Out | 65.67M |
| PE Ratio | 18.63 |
| Forward PE | 34.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,531 |
| Open | 248.11 |
| Previous Close | 249.36 |
| Day's Range | 246.66 - 250.23 |
| 52-Week Range | 203.80 - 282.15 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 314.54 (+27.2%) |
| Earnings Date | Aug 13, 2026 |
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $314.54, which is an increase of 27.20% from the latest price.
News
Ascendis Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $345 price target The firm believes the shares at current levels are underpricing the Yuviwel launch. The…
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasi...
BMO starts Ascendis at Outperform on further platform growth
BMO Capital initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $319 price target The firm says Ascendis has delivered three FDA approvals with its proprietary TransCon platform...
Ascendis Pharma initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $319 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considered a…
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injecti...
Ascendis Pharma reports Q2 EPS 90c, consensus 77c
Reports Q2 revenue $339.29M, consensus $329.9M. “Our patient focus has driven achievement of important milestones and strong demand for our TransCon products as Ascendis continues to transform into a ...
Ascendis Pharma price target lowered to $329 from $345 at Barclays
Barclays lowered the firm’s price target on Ascendis Pharma (ASND) to $329 from $345 and keeps an Overweight rating on the shares. The firm updated the company’s model for its…
Ascendis Pharma price target raised to $341 from $325 at TD Cowen
TD Cowen raised the firm’s price target on Ascendis Pharma (ASND) to $341 from $325 and keeps a Buy rating on the shares. The firm updated its model following solid…
Ascendis Pharma price target raised to $290 from $280 at RBC Capital
RBC Capital analyst Luca Issi raised the firm’s price target on Ascendis Pharma (ASND) to $290 from $280 and keeps an Outperform rating on the shares after its Q2 results.
Ascendis Pharma Earnings Call Transcript: Q2 2026
Q2 2026 saw product revenue more than double year-over-year, driven by strong demand for YORVIPATH, SKYTROFA, and the launch of UBEGLA. The company remains on track for its Vision 2030 revenue goals, with robust global uptake, high patient retention, and ongoing pipeline expansion.
Ascendis Pharma Earnings release: Q2 2026
Ascendis Pharma released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Ascendis Pharma Reports Second Quarter 2026 Financial Results
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ®
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thur...
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.
Ascendis Pharma Slides: Study update presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Ascendis Pharma price target raised to $275 from $256 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Ascendis Pharma (ASND) to $275 from $256 and keeps an Overweight rating on the shares. Q2 earnings should reinforce a shift from…
Ascendis Pharma Slides: Study result presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Ascendis Pharma price target raised to $280 from $275 at RBC Capital
RBC Capital raised the firm’s price target on Ascendis Pharma (ASND) to $280 from $275 and keeps an Outperform rating on the shares as part of a broader research note…
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial
Ascendis Pharma (ASND) announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP in children with achondroplasia. In the trial, TransCon CNP-t...
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly T...
Ascendis Pharma added to multiple Russell U.S. Indexes
Ascendis Pharma (ASND) announced that the company has been added to the broad-market Russell 3000 Index, the large-cap Russell 1000 Index, the small-to-mid-cap Russell 2500 Index, and the Russell Midc...
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell...
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with...
Ascendis Pharma completes Phase 3 PaTHway Trial
Ascendis Pharma (ASND) announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH demonstrated sustained efficacy and safety in adults with hyp...